Key Details
Price
$15.12Annual EPS
-$16.53Annual ROE
-24.21%Beta
1.78Events Calendar
Next earnings date:
Mar 21, 2025Recent quarterly earnings:
Nov 12, 2024Recent annual earnings:
Mar 21, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
CARGO Therapeutics, Inc. (CRGX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
CARGO Therapeutics, Inc. (CRGX) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
The cancer-focused biotech published its second-quarter results. Its loss was much narrower than analysts had expected.
CARGO Therapeutics Adds Experienced Biopharma Executive to Board of Directors with the Appointment of Jane Pritchett Henderson as Independent Director
SAN CARLOS, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (NASDAQ: CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients, today announced that the company will be participating in the following investor conferences.
CARGO Therapeutics, Inc. (CRGX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
The consensus price target hints at a 56.3% upside potential for CARGO Therapeutics, Inc. (CRGX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
SAN MATEO, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (NASDAQ: CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients, today announced that the company will participate in the 42nd Annual J.P. Morgan Healthcare Conference, taking place January 8-11, 2024, in San Francisco, California.
Cargo Therapeutics CRGX, , a clinical-stage biotech specializing in cancer treatments, said late Thursday its initial public offering priced at $15 a share, the low end of its range. The company sold 18.8 million shares to raise $282 million at a valuation of $580.5 million.
Cargo Therapeutics, Inc. has filed for an IPO to raise $300 million for the development of its drug candidates for large B cell lymphoma cancer and other B cell malignancies. The IPO appears reasonably priced, but biopharma IPOs have performed poorly in the recent IPO environment. The market for treatments of diffuse large B-cell lymphoma is expected to reach $7.9 billion by 2030, driving the growth of CARGO Therapeutics.
FAQ
- What is the primary business of CARGO Therapeutics?
- What is the ticker symbol for CARGO Therapeutics?
- Does CARGO Therapeutics pay dividends?
- What sector is CARGO Therapeutics in?
- What industry is CARGO Therapeutics in?
- What country is CARGO Therapeutics based in?
- When did CARGO Therapeutics go public?
- Is CARGO Therapeutics in the S&P 500?
- Is CARGO Therapeutics in the NASDAQ 100?
- Is CARGO Therapeutics in the Dow Jones?
- When was CARGO Therapeutics's last earnings report?
- When does CARGO Therapeutics report earnings?
- Should I buy CARGO Therapeutics stock now?